Document is current
Any future updates will be listed below
-
Authors
Muratov, Sergei
Canelo-Aybar, Carlos
Tarride, Jean-Eric
Alonso-Coello, Pablo
Dimitrova, Nadya
Borisch, Bettina
Castells, Xavier
Duffy, Stephen W.
Fitzpatrick, Patricia
Follmann, Markus
Giordano, Livia
Hofvind, Solveig
Lebeau, Annette
Quinn, Cecily
Torresin, Alberto
Vialli, Claudia
Siesling, Sabine
Ponti, Antonio
Giorgi Rossi, Paolo
Schünemann, Holger
Nyström, Lennarth
Broeders, Mireille https://orcid.org/0000-0002-8741-8148
,
Autelitano, Mariangela
Colzani, Edoardo
Daneš, Jan
Gräwingholt, Axel
Ioannidou-Mouzaka, Lydia
Knox, Susan
Langendam, Miranda
McGarrigle, Helen
Pérez Gómez, Elsa
van Engen, Ruben
Warman, Sue
Young, Kenneth
van Landsveld-Verhoeven, Cary
Lerda, Donata
Saz-Parkinson, Zuleika
Parmelli, Elena
Janusch-Roi, Annett
-
Funding
Funding for this research was provided by:
European Commission, Joint Research Centre Ispra, Italy (Not applicable)
- License Information
-
More Information
Article History
Received: 17 January 2020
Accepted: 11 August 2020
First Online: 24 August 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Dr. Muratov reports personal fees from Joint Research Center (European Commission), during the conduct of the study.Dr. Canelo-Aybar, Dr. Alonso Coello and Dr. Valli report grants from Joint Research Center (European Commission), during the conduct of the study.Dr. Tarride reports other from European Union, during the conduct of the study; grants and other from Allergan, AstraZeneca, Amgen, CSL Behring, Janssen, Lilly, Novo Nordisk, Sage, Assurex/Myriad, Edwards Lifesciences, Pfizer, Roche, Merck, GlaxoSmithKline, Evidera, PCDI, CADTH., outside the submitted work;Dr. Dimitrova reports Employee of the European Commission Joint Research Centre.Dr. Lebeau reports non-financial support from European Commission, during the conduct of the study; and Dr. Lebeau is chair of the Breast Pathology Working Group of the German S3 Guidelines for the Early Detection, Diagnosis, Treatment and Follow up of Breast Cancer, a member of the Scientific Advisory Council for the Cooperation Alliance Mammography (Kooperationsgemeinschaft Mammographie GBR), Germany, member of the certification commission “breast cancer centres” as a representative of the German Society of Pathology and the Federal Association of German Pathologists, and board member of the German Society of Pathology and the German Society of Senology.Dr. Giorgi Rossi reports the following activities:05/2010–05/2012 – GISMa, Italy, −Type: NGO. Member of the coordinating group of the Italian Scientific Society on Mammographic screening. 2008–2012- ONS, Italy, −Type: Governmental. Member of the Steering committee of the National Centre for screening monitoring. 2012- today, − ONS, Italy -Type: Governmental. Consultant for the National Centre for screening monitoring (institutional duty, unpaid work). Sept/2018- today -Ispro, Toscana, Italy -Type: Governmental. Member of the Scientific committee (institutional duty, unpaid work). I have published opinions about the superiority of public, organised, population-based screening programs instead of opportunistic and private screening, according to the EC recommendations 2003/878/EC.Besides corresponding individual COIs, if any, Dr. Borisch, Dr. Broeders, Dr. Castells, Dr. Duffy, Dr. Fitzpatrick, Dr. Follmann, Dr. Giordano, Dr. Hofvind, Dr. Nyström, Dr. Quinn, Dr. Torresin, Dr. Schünemann (co-chair of the ECIBC GDG and co-chair of the GRADE working group) report being members of the ECIBC GDG; Dr. Ponti and Dr. Siesling are members of the ECIBC QASDG.
